1 Thing to Know Before Betting on the Next Blockbuster Drug
The guest on this week's nationally syndicated Motley Fool Money radio show is Ron Adner, an award-winning professor and author of the new book The Wide Lens: A New Strategy for Innovation. In the past decade, major pharmaceutical companies such as Eli Lilly, Pfizer, and MannKind were in a race to be the first to market an inhalable insulin. In this audio segment, Adner details how Pfizer did everything right, only to fail on a massive scale. Adner provides shareholders of pharmaceutical companies a key insight into what those companies need if they want to succeed in creating the next blockbuster drug.
Johnson & Johnson is just one of the companies in The Motley Fool's report featuring some of the biggest and best-known brand names in global business. It's called "Secure Your Future With 11 Rock-Solid Dividend Stocks," and you can get access it to it right now at no cost. Simply click here -- it's free.
At the time this article was published Chris Hillowns shares of Pfizer.Motley Fool newsletter serviceshave recommended buying shares of Pfizer. Try any of our Foolish newsletter servicesfree for 30 days. We Fools don't all hold the same opinions, but we all believe thatconsidering a diverse range of insightsmakes us better investors. The Motley Fool has adisclosure policy.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.